April 24th 2024
Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
IQVIA Report Boasts Biosimilar Uptake in Europe, Sheds Light on What’s to Come
January 10th 2023IQVIA’s eighth edition of its Impact of Biosimilar Competition in Europe report demonstrated successful uptake in many countries throughout the region. However, not every country has great adoption rates and companies may have a harder time choosing which molecules to invest in for biosimilar development.
TNF Inhibitor Biosimilar Use in France
December 31st 2022A study assessing the use of tumor necrosis factor (TNF) alpha inhibitor biosimilars in France found that the biosimilar penetration rate was higher for infliximab compared to etanercept and adalimumab. The authors said they aimed to understand the key drivers for biosimilar use to improve biosimilar uptake in France.
Prescribers’ Perspectives on Strategies for Increasing Biosimilar Adoption
December 17th 2022Despite recent steps taken by the FDA to streamline approvals and increase availability for biosimilars, biosimilar adoption has been slow and primarily driven by payers in the United States, signaling that more needs to be done to encourage adoption, according to experts at a virtual workshop hosted by the FDA and the University of Maryland.
Prime Therapeutics Completes Acquisition of Magellan Rx Management
December 6th 2022Prime Therapeutics has officially acquired Magellan Rx Management, a popular pharmacy benefit manager (PBM) in the specialty pharmacy space. The acquisition was announced in May 2022 and includes the acquisition of Magellan Rx’s specialty, PBM, and government pharmaceutical and Medicaid business segments.
Dr Ivo Abraham Column: 1 Billion People Can Access Biosimilars; What About the Other 7 Billion?
November 30th 2022Now that the world population has reached 8 billion, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, took a look at how high-income countries can increase accessibility to livesaving medicines to the 7 billion people who have limited access to biosimilars.
Regence: Biosimilar Adoption Leads to $37 Million Reduction in Annual Spending
November 28th 2022Regence found that implementing strategies to increase its biosimilar adoption rate reduced spending on specialty drugs by $37 million annually. The organization is the latest example of how biosimilar use has contributed to significant savings.
AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars
November 8th 2022Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.
AAM Report: Biosimilars, Generics Generated Billions of Dollars in Savings in 2021
November 1st 2022Biosimilar and generic drugs accumulated $373 billion in savings in 2021, $7 billion of which can be attributed to biosimilars alone, according to a report from the Association for Accessible Medicines (AAM).
Cardinal Health Reports Increased Confidence in Biosimilars Among Rheumatologists
October 22nd 2022A report from Cardinal Health tells that rheumatologists are more familiar and confident in biosimilars compared with 2020, showing that education efforts are effective and that rheumatologists are more willing to prescribe biosimilars to their patients.
Dr Ryan Haumschild Compares Viewpoints on Biosimilar Value Between Stakeholders
October 4th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, explains how stakeholders may view the economic value of biosimilars differently based on their goals and his predictions for how biosimilar utilization will develop in the future.
Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts
September 23rd 2022Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.
Contributor: Interchangeability Is a Dispensing Issue, Not a Prescribing One
September 15th 2022As more biosimilars are granted interchangeability status, 2 representatives from Samsung Bioepis stop misinformation in its tracks by clarifying that the designation will primarily impact pharmacy dispensing instead of prescription habits.
Dr Ivo Abraham Column: It's What We Do With the Savings—Economics and Equity
August 30th 2022Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, describes the pharmacoeconomics of biosimilars and the savings potential for practices and payers if they prioritize greater biosimilar adoption.
Vizient Survey Reveals Provider Motivations for Choosing Biosimilar Over Humira
August 23rd 2022Vizient’s 2022 Biosimilar Survey found that health care organizations consider interchangeable designations to be very important in prescription decision-making, signaling the interchangeability could play a big role in the adoption of adalimumab biosimilars.
Biosimilar Infliximab Deemed Safe, Effective in Pediatric Patients With IBD
August 22nd 2022Researchers found that an infliximab biosimilar was as safe and effective as the reference product (Remicade) in pediatric patients with inflammatory bowel disease. However, more studies on adalimumab biosimilars in pediatric patients are needed.
Study: Biosimilar Uptake, Rather Than Competition, Will Influence Price Decreases
August 15th 2022Researchers found that the percentage of biosimilar uptake is a better predictor of whether prices of biologics will significantly decrease, refuting the argument that more biosimilars for a single reference product will have the biggest impact.
Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023
August 2nd 2022Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.
Contributor: Good Bait and Fair Switch—Biosimilar Interchangeability, Substitution, and Choice
July 11th 2022Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board, explains the difference between biosimilar interchangeability and substitution and weighs in on whether switching studies are necessary.
Survey: Most Patients Received Inadequate Information About Switching to a Trastuzumab Biosimilar
July 9th 2022A survey study found that many patients with breast cancer reported receiving inadequate information regarding switching from Herceptin to a trastuzumab biosimilar, with some patients reporting that they were never told a switch occurred or what a biosimilar was.
Medicines for Europe Recommends Off-Patent Drugs to Strengthen European Health Systems
July 5th 2022During its annual conference in Sitges, Spain, Medicines for Europe recommended policy reforms for strengthening European health systems, including the use of off-patent medications like biosimilar and generic drugs.